Georg Wensing

Wuppertal, NW 42096, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis.

Safety of healthy subjects in first-in-human multiple-dose studies: A pooled analysis.

Journal: International journal of clinical pharmacology and therapeutics

Published: September 29, 2020

How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum.

How to Interpret an Investigator's Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum.

Journal: Therapeutic innovation & regulatory science

Published: May 07, 2020

How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016 .

How safe are our studies? Analysis of adverse events in Bayer First-in-Human trials from 2006 to 2016 .

Journal: International journal of clinical pharmacology and therapeutics

Published: November 21, 2019

First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.

First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.

Journal: British journal of clinical pharmacology

Published: September 05, 2017

Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

Who is a 'healthy subject'?-consensus results on pivotal eligibility criteria for clinical trials.

Journal: European journal of clinical pharmacology

Published: November 09, 2016

Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Journal: Pulmonary circulation

Published: May 11, 2016

Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521).

Journal: Pulmonary circulation

Published: May 11, 2016

Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

Bioavailability, pharmacokinetics, and safety of riociguat given as an oral suspension or crushed tablet with and without food.

Journal: Pulmonary circulation

Published: May 11, 2016

Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.

Pharmacokinetic interaction study between riociguat and the combined oral contraceptives levonorgestrel and ethinylestradiol in healthy postmenopausal women.

Journal: Pulmonary circulation

Published: May 11, 2016

Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.

Riociguat (BAY 63-2521) and aspirin: a randomized, pharmacodynamic, and pharmacokinetic interaction study.

Journal: Pulmonary circulation

Published: May 11, 2016

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.

Journal: Fundamental & clinical pharmacology

Published: August 18, 2015

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers.

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers.

Journal: Clinical pharmacology : advances and applications

Published: March 28, 2014

Showing 1-12 of 15

Last Updated: 09/26/2026